EUVIMEDEUVIMED entdecken
Open Access

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease

Nabil Noureddin, Daniel Q Huang iD, Ricki Bettencourt, Harris Siddiqi, Abdul M Majzoub, Tarek Nayfeh iD, Nobuharu Tamaki iD, Namiki Izumi, Atsushi Nakajima iD, Ramazan Idilman, Mesut Gumussoy, Digdem Kuru Oz und 5 weitere

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17981 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Nabil Noureddin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology and Hepatology, MASLD Research Center, University of California at San Diego, La Jolla, Californ…. Hauptthemen laut MEDLINE: Disease Progression, Hepatic Encephalopathy, Ascites, Fatty Liver. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, Singapore Ministry of Health's National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims The natural progression of hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease (MASLD) is not well‐characterised. We aimed to describe it by conducting a retrospective analysis.

Methods

This longitudinal, retrospective analysis of well‐characterised MASLD cohorts followed for hepatic decompensation and death. The sequence of liver‐related events was evaluated, and the median time between hepatic decompensation episodes and death versus. transplantation was measured.

Results

Of the 2016 patients identified, 220 (11%) developed at least one episode of hepatic decompensation during a median follow‐up of 3.2 years. Ascites was the most common first liver‐related event [153 (69.5%)], followed by hepatic encephalopathy (HE) [55 (25%)] and variceal haemorrhage (VH) [30 (13.6%)]. Eighteen out of the 220 (8.1%) patients had more than one liver‐related event as their first hepatic decompensation. Among the patients who had the first episode, 87 (39.5%) had a second episode [44 (50.5%) HE, 31 (35.6%) ascites, and 12 (13.7%) VH]. Eighteen out of 220 (8.1%) had a third episode [10 (55.5%) HE, 6 (33.3%) VH, and 2 (11.1%) ascites]. Seventy‐three out of 220 (33.1%) died, and 31 (14%) received liver transplantation. The median time from the first episode to the second was 0.7 years and 1.3 years from the second episode to the third. The median survival time from the first episode to death or transplantation was 2.0 years.

Conclusion

The most common first liver‐related event in MASLD patients is ascites. The median survival from the first hepatic decompensation to either death or transplantation is 2 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ProgressionHepatic EncephalopathyAscitesFatty LiverHumansMaleFemaleRetrospective StudiesMiddle AgedLongitudinal StudiesAdultAgedLiver TransplantationGastrointestinal HemorrhageMetabolic Diseases

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology and Hepatology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
  • Department of Medicine, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.
  • Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.

ORCID-Profile: Daniel Q Huang, Tarek Nayfeh, Nobuharu Tamaki, Atsushi Nakajima, Tolga Gidener, Rohit Loomba

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • Singapore Ministry of Health's National Medical Research Council
  • NIAAA NIH HHS
  • John C Martin Foundation
  • NHLBI NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advancing Translational Sciences

Zitieren

APA

Noureddin, N., Huang, D. Q., Bettencourt, R., Siddiqi, H., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idilman, R., Gumussoy, M., Oz, D. K., Erden, A., Gidener, T., Allen, A. M., Ajmera, V., & Loomba, R. (2024). Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17981

Vancouver

Noureddin N, Huang DQ, Bettencourt R, Siddiqi H, Majzoub AM, Nayfeh T, et al. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17981

BibTeX
@article{Noureddin2024,
  author = {Noureddin, Nabil and Huang, Daniel Q and Bettencourt, Ricki and Siddiqi, Harris and Majzoub, Abdul M and Nayfeh, Tarek and Tamaki, Nobuharu and Izumi, Namiki and Nakajima, Atsushi and Idilman, Ramazan and Gumussoy, Mesut and Oz, Digdem Kuru and Erden, Ayse and Gidener, Tolga and Allen, Alina M and Ajmera, Veeral and Loomba, Rohit},
  title = {Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17981}
}
Kostenlos starten →